Cargando…
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
Autores principales: | Zhang, Hao, Hu, Yongxian, Chang, Alex H., Huang, He |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965727/ https://www.ncbi.nlm.nih.gov/pubmed/31988993 http://dx.doi.org/10.1016/j.reth.2019.11.003 |
Ejemplares similares
-
Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022) -
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
por: Martinez-Serra, Jordi, et al.
Publicado: (2014) -
Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018) -
Expression of chronic myeloid leukemia oncogenes BCR-ABL
(P210)
and BCR-ABL
(T315I)
affect cellular and humoral innate immunity in
Drosophila melanogaster
por: Abubaker, Dana, et al.
Publicado: (2022) -
Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case
por: Al-Achkar, Walid, et al.
Publicado: (2014)